foxo4-dri senolytic peptide human trials FOXO4-DRI: Trial Status, Cancer Research & Data FOXO4-DRI (FOX04-DRI) 10mg Peptide |
FOXO4 DRI (FOX04 DRI) 10mg Peptide Luxe Peptides The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI Nature Communications Molecular modelling of the FOXO4 TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells ScienceDirect Frontiers Senolytic Peptide FOXO4 DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes FOXO4 DRI Averix Labs
Pay in 4 interest-free payments of $5.75 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 5 - Aug 10




